Return to homepagePandemic Pact

Proactive protection of inpatients with COVID-19 lung disease - Pro-Lung-COVID trial,

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Known Financial Commitments (USD)

    $346,023.36

  • Funder

    Novo Nordisk Foundation

  • Research Location

    Denmark

  • Lead Research Institution

    University of Copenhagen and Capital Region of Denmark

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Clinical trials for disease management

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The project will examine whether internal medicine patients hospitalized acutely who have tested positive for 2019-nCoV can benefit from treatment with the drug hydroxychloroquine, which is used to combat viral infection, and the antiviral, immunomodulatory and antibacterial drug azithromycin. The aim is to find a treatment that can reduce hospitalization time, the number of admissions to intensive care units and mortality.